COPENHAGEN (Reuters) – Danish drugmaker Lundbeck and Japan’s Otsuka Pharmaceutical on Monday announced positive Phase III results for its brexpiprazole drug used to treat agitation in patients with Alzheimer’s-type dementia.
The two companies are planning a regulatory filing to the U.S. Food and Drug Administration later in 2022, Lundbeck said in a statement.
(Reporting by Stine Jacobsen, editing by Terje Solsvik)
